Navigation Links
Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin®
Date:7/6/2010

MELVILLE, N.Y., July 6 /PRNewswire/ -- E. Fougera & Co., a leading specialty pharmaceutical manufacturer, announced it has received first generic approval from the FDA for Adapalene Cream 0.1% (Rx).  Fougera's Adapalene Cream 0.1% is rated AB, generically equivalent to Differin® by Galderma Pharmaceuticals. According to industry data, U.S. sales of the brand named product in 2009 exceeded $55 million. This approval also marks the fourth product approval that the FDA has granted to Fougera this year.

"Fougera's commitment to develop this first-to-market product as a cost-effective generic provides healthcare professionals the ability to prescribe a more affordable treatment, thereby making it accessible to more patients," said David Klaum, Sr. Vice President and General Manager of Fougera.

Adapalene Cream 0.1% is indicated for the treatment of acne vulgaris. Full Prescribing Information for Adapalene Cream 0.1% is available at www.fougera.com or can be requested by calling (800) 645-9833.

Important Safety Information

Adapalene cream 0.1% is indicated for the topical treatment of acne vulgaris in patients 12 years and older. The most common side effects reported with use of adapalene 0.1% products include itching, dryness, redness, stinging, burning, and scaling or peeling. Most adverse events reported were mild to moderate in severity, occurred early in treatment and decreased thereafter. Excessive exposure to sunlight and sunlamps should be avoided during treatment and use of sunscreen products and protective clothing is recommended. As with other acne medications, overexposure to extreme wind or cold or use of irritating skin care products may aggravate the skin.  Patients should talk to the doctor if these effects become bothersome.  

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Fougera

Founded in 1849, Fougera is a division of Nycomed US Inc. and is the leading manufacturer and distributor of a wide range of topical products. For more information on Fougera's complete line of products, please call Fougera Customer Service at (800) 645-9833 or visit the company online at www.fougera.com.

About Nycomed US Inc.

Nycomed US Inc. is a subsidiary of Nycomed.  In addition to Fougera, Nycomed US Inc. operates two additional divisions of specialty pharmaceuticals.  The PharmaDerm division is dedicated to developing and commercializing novel prescription products to treat diseases and conditions of the skin—the largest organ of the human body.  Nycomed US Inc. also markets and sells Savage Laboratories products, which focus on emergency care.  More information is available at www.nycomedus.com.


'/>"/>
SOURCE Fougera
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016 According to responses from U.S. oncologists that ... of patients with non-small cell lung cancer (NSCLC), treatment decisions ... genetic mutation status. The findings of the survey were presented ... #P3.02b ) at the 2016 World Conference on Lung ... The survey results revealed an overall high rate of ...
(Date:12/7/2016)... Dec. 7, 2016 Boehringer Ingelheim today ... patients with unresectable malignant pleural mesothelioma (MPM) met ... data, presented at the 17 th IASLC ... Vienna , showed nintedanib plus pemetrexed/cisplatin demonstrated ... pemetrexed/cisplatin, with a significantly improved PFS (9.4 vs ...
(Date:12/7/2016)... YORK , December 7, 2016 ... Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. ... DNAI ), and AveXis Inc. (NASDAQ: AVXS ... Sector Index fell roughly 37% to reach a level equal ... it is down by approximately 14% for the year, it ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... AlignLife clinics nationwide are giving back to their communities by collecting ... bountiful gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the ... , In exchange for generous donations, customers will receive a gift in return. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the ... and Your Health on Voice of America, declared on her radio program in November ... the fact that when these bullies attack leaders in corporate America, they are trying ...
(Date:12/7/2016)... ... , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday Deals ... To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , Delete® ... Deals on Botox® and Juvederm® just in time for the holiday party season. ...
(Date:12/7/2016)... ... 2016 , ... The medical profession is well aware that heart attacks do ... analyzing heart attacks among 138,602 people recorded a 35% higher number of heart attacks ... agree of course–no time of year is a good time for a heart attack! ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):